Chadi Nabhan, MD, MBA, FACP

Chadhi Nabhan, MD, MBA, FACP, is a hematologist/oncologist and award-winning host of the “Outspoken Oncology” and “Healthcare Unfiltered” podcasts.

Articles by Chadi Nabhan, MD, MBA, FACP

Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 18, 2023
Drs. Vijenthira and Prica discuss their study and why its results differed from a similar study published in late 2022.
Listen Now
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 4, 2023
Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma and key MRD considerations.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 20, 2023
Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma and the nuances involved.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 6, 2023
Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates and treatment considerations.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 23, 2023
Drs. Kambhampati and Thiruvengadam discuss their study investigating the cost effectiveness of pola-R-CHP in DLBCL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 9, 2023
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Chadi Nabhan, MD, MBA, FACPViewpoints | February 24, 2023
Dr. Nabhan discusses his new book, "Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice."
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 23, 2023
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 9, 2023
Dr. Sehn also explains why the TRIANGLE study is anticipated to change practices surrounding transplant in MCL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 26, 2023
Sanam Loghavi, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about why 2022 was a major year for MDS.
Chadi Nabhan, MD, MBA, FACPViewpoints | January 13, 2023
As 2023 begins, you'll want to listen to The HemOnc Pulse, a new podcast that brings you the latest in hematologic oncology.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 12, 2023
In this episode, Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, about CLL highlights from ASH 2022.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 29, 2022
Ruben Mesa, MD, discusses his career in MPN treatment and research and notable abstracts at the 2022 ASH Annual Meeting.
Chadi Nabhan, MD, MBA, FACPVideo Insights | December 20, 2022
Chadi Nabhan, MD, MBA, FACP, interviews Srdan Verstovsek, MD, on highlights in MPN research at the 2022 ASH Annual Meeting.
Chadi Nabhan, MD, MBA, FACPVideo Insights | December 20, 2022
Robert Orlowski, MD, PhD, discusses bispecific antibodies and novel targets in myeloma with Chadi Nabhan, MD, MBA, FACP.
Chadi Nabhan, MD, MBA, FACPVideo Insights | December 19, 2022
Watch as Chadi Nabhan, MD, MBA, FACP, interviews Jeffrey Lancet, MD, about novel and targeted therapies for AML.
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | December 16, 2022
Naval Daver, MD, checks in at The HemOnc Pulse to discuss AML in the elderly and the emergence of venetoclax.
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | December 16, 2022
John DiPersio, MD, PhD, discusses menin inhibitors, current challenges in treating AML, the role of transplant, and more.
Chadi Nabhan, MD, MBA, FACPMantle Cell Lymphoma | December 16, 2022
Tycel Phillips, MD, of the City of Hope, talks about the TRIANGLE study and frontline therapy in mantle cell lymphoma.
Chadi Nabhan, MD, MBA, FACPMyeloma | December 14, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses novel therapies in myeloma, MRD data, and more.